Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 220 participants.

Also called NCT03844594

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03844594
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03844594. Allocation not applicable; no masking; primary purpose treatment. Start 2019-04-06 (actual); primary completion 2020-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Eptifibatide in Endovascular Treatment of Acute Ischemic Stroke (EPOCH)
Condition
Acute Ischemic Stroke
Intervention (Drug)
Eptifibatide Injection
Lead sponsor
Ministry of Science and Technology of the People´s Republic of China (class: other government)

Record details

Record id
cardio:ct-nct03844594
Content hash
3eee5c29417de8f1caba940513518826a137099d3647c11f03c038118f1b7198